Drugs / Elsunersen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07019922 | Aug 2025 → Jun 2026 overdue | genetic developmental and epileptic encephalopathy | Praxis Precision Medicines | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-06-22 | Praxis Precision Medicines | Regulatory Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants praxismedicines.com ↗
The Breakthrough Therapy Designation (BTD) was granted based on the positive results from the EMBRAVE Part A trial of elsunersen |
| 2026-04-06 | Praxis Precision Medicines | Results Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy praxismedicines.com ↗ |
All press releases naming this drug 2 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Elsunersen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07019922 ↗ |
| Route | Intrathecal | “intrathecally” NCT07019922 ↗ |